We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Boston Scientific (BSX) Outpaced the Stock Market Today
Read MoreHide Full Article
Boston Scientific (BSX - Free Report) closed at $104.33 in the latest trading session, marking a +1.09% move from the prior day. This change outpaced the S&P 500's 0.14% gain on the day. Elsewhere, the Dow gained 0.2%, while the tech-heavy Nasdaq added 0.27%.
Prior to today's trading, shares of the medical device manufacturer had gained 3.47% outpaced the Medical sector's loss of 1.34% and lagged the S&P 500's gain of 3.97%.
Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to go public on July 23, 2025. On that day, Boston Scientific is projected to report earnings of $0.72 per share, which would represent year-over-year growth of 16.13%. Meanwhile, our latest consensus estimate is calling for revenue of $4.89 billion, up 18.69% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $2.91 per share and revenue of $19.5 billion. These totals would mark changes of +15.94% and +16.42%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.05% upward. Boston Scientific is currently a Zacks Rank #2 (Buy).
Looking at valuation, Boston Scientific is presently trading at a Forward P/E ratio of 35.4. This valuation marks a premium compared to its industry average Forward P/E of 19.64.
Meanwhile, BSX's PEG ratio is currently 2.68. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 2.26 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 148, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Boston Scientific (BSX) Outpaced the Stock Market Today
Boston Scientific (BSX - Free Report) closed at $104.33 in the latest trading session, marking a +1.09% move from the prior day. This change outpaced the S&P 500's 0.14% gain on the day. Elsewhere, the Dow gained 0.2%, while the tech-heavy Nasdaq added 0.27%.
Prior to today's trading, shares of the medical device manufacturer had gained 3.47% outpaced the Medical sector's loss of 1.34% and lagged the S&P 500's gain of 3.97%.
Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to go public on July 23, 2025. On that day, Boston Scientific is projected to report earnings of $0.72 per share, which would represent year-over-year growth of 16.13%. Meanwhile, our latest consensus estimate is calling for revenue of $4.89 billion, up 18.69% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $2.91 per share and revenue of $19.5 billion. These totals would mark changes of +15.94% and +16.42%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.05% upward. Boston Scientific is currently a Zacks Rank #2 (Buy).
Looking at valuation, Boston Scientific is presently trading at a Forward P/E ratio of 35.4. This valuation marks a premium compared to its industry average Forward P/E of 19.64.
Meanwhile, BSX's PEG ratio is currently 2.68. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 2.26 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 148, putting it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.